Nvidia dives deeper into AI drug development with Amgen, Recursion partnerships

Nvidia Corp. NVDA, +4.83% is doubling down on artificial-intelligence-powered drug discovery and development, announcing expanded partnerships Monday with Amgen Inc. AMGN, +1.35% and Recursion Pharmaceuticals Inc. RXRX, +3.65%. Amgen subsidiary deCODE Genetics is building out an Nvidia supercomputer to create genomics “foundation models” — models trained on massive datasets to tackle a variety of jobs — to fuel drug discovery, Nvidia said Monday at the JPMorgan Chase & Co. JPM, -1.50% healthcare conference ...